Inovio Pharmaceuticals Inc., a biotechnology company specializing in DNA medicines for HPV-related diseases, cancer, and infectious diseases, has announced a proposed public offering of its common stock or pre-funded warrants, along with Series A and Series B warrants. This underwritten public offering is subject to market conditions and may include a 30-day option for the underwriter to purchase additional shares or warrants. Piper Sandler & Co. is serving as the sole book-running manager. The offering will proceed only through a written prospectus and prospectus supplement, which will be filed with the SEC and made available on their website.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。